NCT02603614View on ClinicalTrials.gov

Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Heart FailureRenal Insufficiency
Interventions
DRUG

Cenderitide

Cenderitide is a dual receptor natriuretic peptide.

DRUG

Placebo

Placebo control

Trial Locations (1)

92780

Orange County Research Center, Tustin

All Listed Sponsors
lead

Capricor Inc.

INDUSTRY

NCT02603614 - Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment | Biotech Hunter | Biotech Hunter